حجم سوق اللقاحات السفر، وتحليل الحصة والاتجاهات المستقبلية بحلول عام 2032.

Q: What is the growth rate of the Travel Vaccine Market?

The Travel Vaccine Market growth rate is 8.9% by 2032. Read More

>السوق العالمية للقاحات السفر، حسب التركيب (اللقاحات المركبة واللقاحات الأحادية)، النوع (اللقاحات المعطلة، واللقاحات الفرعية، واللقاحات المؤتلفة، واللقاحات متعددة السكاريد والمقترنة، واللقاحات الحية المضعفة، واللقاحات التوكسيدية، واللقاحات الحمض النووي، واللقاحات النواقل الفيروسية)، الفئة (اللقاح الموصى به، واللقاح الروتيني، واللقاح المطلوب)، المرض (التيفوئيد، والتهاب الكبد، والكوليرا، وجدري الماء، والإنفلونزا، والتهاب الدماغ الياباني، والتهاب السحايا بالمكورات السحائية، والحمى الصفراء، وداء الكلب، واللقاح الثلاثي، والحصبة والنكاف، والتهاب الدماغ المنقول بالقراد، والملاريا، وكوفيد-19، وشلل الأطفال، وغيرها)، طريق الإعطاء (عن طريق الحقن والفم)، الجنس (ذكر وأنثى)، نوع المريض (بالغ، وطفل، وكبار السن)، الفئة العمرية (20-50 سنة، أقل من 20 سنة) السنوات، وما فوق 50 عامًا، وقنوات التوزيع (B2B وB2C) - اتجاهات الصناعة وتوقعاتها حتى عام 2032.

تحليل ورؤى حول سوق لقاحات السفر

مع العولمة وسهولة الوصول إلى السفر، يسافر المزيد من الناس إلى وجهات حول العالم. يؤدي هذا النشاط المتزايد في السفر إلى زيادة التعرض للأمراض المعدية المنتشرة في مناطق مختلفة، مما يدفع الطلب على لقاحات السفر لحماية الأفراد من الإصابة بأمراض مثل الحمى الصفراء والتيفوئيد والتهاب الكبد أ وغيرها. على الرغم من أن أحد القيود الأساسية على لقاحات السفر هو التكلفة وسهولة الوصول إليها. يمكن أن تكون لقاحات السفر باهظة الثمن، وخاصة للأفراد الذين قد يسافرون إلى وجهات متعددة تتطلب تطعيمات مختلفة. بالإضافة إلى ذلك، قد يكون الوصول إلى خدمات الرعاية الصحية وعيادات التطعيم محدودًا في مناطق معينة، مما يجعل من الصعب على المسافرين تلقي التطعيمات اللازمة قبل رحلاتهم. تقدم التطورات في تكنولوجيا اللقاحات، مثل تطوير طرق توصيل جديدة أو عمليات تصنيع أكثر كفاءة، فرصًا لتحسين فعالية لقاحات السفر وإمكانية الوصول إليها وبأسعار معقولة. يمكن أن تعمل الابتكارات مثل لقاحات الحمض النووي أو لقاحات mRNA أو بقع الإبر الدقيقة على تعزيز تطوير وتوزيع لقاحات السفر، مما يجعلها متاحة على نطاق أوسع وفعالة من حيث التكلفة. على الرغم من أن التردد في اللقاح والمعلومات المضللة تشكل تحديات كبيرة للقاحات السفر. قد يتردد بعض الأفراد في تلقي التطعيمات بسبب مخاوف بشأن السلامة أو الفعالية أو المفاهيم الخاطئة حول الأمراض التي تحمي من الإصابة بها. إن معالجة التردد في تلقي اللقاحات ومكافحة المعلومات المضللة من خلال التعليم وجهود التوعية وحملات الاتصال أمر بالغ الأهمية لضمان فهم المسافرين لأهمية اللقاحات في حماية صحتهم ومنع انتشار الأمراض المعدية عبر الحدود.

تحلل شركة Data Bridge Market Research أن سوق لقاحات السفر العالمية من المتوقع أن يصل إلى 13.09 مليار دولار أمريكي بحلول عام 2032 من 6.14 مليار دولار أمريكي في عام 2023، بمعدل نمو سنوي مركب كبير يبلغ 8.9٪ في الفترة المتوقعة من 2024 إلى 2032.

تقرير القياس	تفاصيل
فترة التنبؤ	2024 إلى 2032
سنة الأساس	2023
سنوات تاريخية	2022 (قابلة للتخصيص للفترة 2016-2021)
وحدات كمية	الإيرادات بالمليار دولار أمريكي
القطاعات المغطاة	التركيب (اللقاحات المركبة واللقاحات الأحادية)، النوع (اللقاحات المعطلة، واللقاحات الفرعية، واللقاحات المعاد تركيبها ، واللقاحات متعددة السكاريد والمقترنة، واللقاحات الحية المضعفة، واللقاحات التوكسيدية، واللقاحات الحمض النووي، واللقاحات النواقل الفيروسية)، الفئة (اللقاح الموصى به، واللقاح الروتيني، واللقاح المطلوب)، المرض (التيفوئيد، والتهاب الكبد، والكوليرا، وجدري الماء، والإنفلونزا، والتهاب الدماغ الياباني، والتهاب السحايا بالمكورات السحائية، والحمى الصفراء، وداء الكلب، واللقاح الثلاثي، والحصبة والنكاف، والتهاب الدماغ المنقول بالقراد، والملاريا، وكوفيد-19، وشلل الأطفال، وغيرها)، طريقة الإعطاء (عن طريق الحقن والفم)، الجنس (ذكر وأنثى)، نوع المريض (بالغ، وطفل، وكبار السن)، الفئة العمرية (20-50 سنة، وأقل من 20 سنة، وفوق 50 سنة) السنوات، قناة التوزيع (B2B وB2C)
الدول المغطاة	الولايات المتحدة الأمريكية، كندا، المكسيك، ألمانيا، المملكة المتحدة، فرنسا، إيطاليا، هولندا، إسبانيا، روسيا، سويسرا، بولندا، النرويج، المجر، النمسا، أيرلندا، ليتوانيا، بقية أوروبا، الصين، اليابان، الهند، كوريا الجنوبية، أستراليا، سنغافورة، تايلاند، إندونيسيا، ماليزيا، الفلبين، فيتنام، بقية دول آسيا والمحيط الهادئ، البرازيل، الأرجنتين، بيرو، بقية دول أمريكا الجنوبية، المملكة العربية السعودية، الإمارات العربية المتحدة، إسرائيل، جنوب أفريقيا، مصر، الكويت، وبقية دول الشرق الأوسط وأفريقيا
الجهات الفاعلة في السوق المشمولة	GSK plc.، Bavarian Nordic، Pfizer Inc.، Abbott، CSL، AstraZeneca، Sanofi، Merck & Co.، Inc.، Valneva SE، Johnson & Johnson Services Inc.، وDynavax Technologies، من بين شركات أخرى

تعريف السوق

لقاحات السفر هي تطعيمات مصممة خصيصًا لحماية الأفراد من الأمراض المعدية التي قد يتعرضون لها أثناء السفر إلى مناطق أو دول مختلفة. يتم إعطاء هذه اللقاحات قبل المغادرة إلى وجهات حيث يوجد خطر التعرض لأمراض غير منتشرة في بلد أو منطقة الفرد الأصلي. تعتمد أنواع اللقاحات الموصى بها على عوامل مختلفة بما في ذلك وجهة المسافر ومدة الإقامة والأنشطة المخطط لها والحالة الصحية الحالية وأي تطعيمات سابقة. الهدف من لقاحات السفر هو منع انتشار الأمراض المعدية وضمان صحة وسلامة المسافرين أثناء رحلاتهم.

ديناميكيات سوق لقاحات السفر العالمية

يتناول هذا القسم فهم محركات السوق والفرص والقيود والتحديات. وسيتم مناقشة كل هذا بالتفصيل أدناه:

السائقين

ارتفاع حالات الإصابة بالأمراض المعدية

مع انتشار الأمراض المعدية أو ظهورها مرة أخرى في مختلف أنحاء العالم، يواجه المسافرون خطرًا متزايدًا للتعرض لهذه العوامل الممرضة أثناء رحلاتهم. قد يتلامس المسافرون مع العوامل المعدية من خلال التفاعل مع السكان المحليين، أو الطعام أو الماء الملوث، أو لدغات الحشرات، أو التعرض للمخاطر البيئية. ويؤكد ارتفاع خطر الإصابة بالعدوى على أهمية التطعيم كإجراء وقائي لحماية المسافرين من الأمراض الخطيرة المحتملة أو التي تهدد الحياة. ويؤدي ارتفاع معدل الإصابة بالأمراض المعدية إلى نمو سوق لقاحات السفر من خلال زيادة المخاطر التي يتعرض لها المسافرون، مما يدفع إلى متطلبات التطعيم الإلزامية، والاستجابة لتفشي الأوبئة، وتعزيز التدابير الوقائية للأمراض المتوطنة، ومعالجة مخاوف الأمن الصحي العالمي.

اللوائح والتوصيات الحكومية بشأن التطعيم

لقد طبقت العديد من البلدان متطلبات التطعيم الإلزامي للمسافرين الذين يدخلون حدودها. وتستند هذه المتطلبات غالبًا إلى انتشار أمراض معينة في مناطق محددة وتهدف إلى تجنب استيراد الأمراض المعدية وانتشارها. على سبيل المثال، قد تطلب البلدان في أفريقيا وأمريكا الجنوبية إثبات التطعيم ضد الحمى الصفراء للمسافرين القادمين من المناطق التي يتفشى فيها المرض. تخلق مثل هذه المتطلبات طلبًا مباشرًا على لقاحات السفر بين المسافرين الذين يحتاجون إلى الامتثال لقواعد الدخول .

ومن ثم، تلعب اللوائح والتوصيات الحكومية المتعلقة بالتطعيم دورًا محوريًا في دفع نمو سوق لقاحات السفر من خلال خلق الطلب، وزيادة الوعي، وتسهيل الوصول إلى خدمات التطعيم للمسافرين. وتعتبر هذه الجهود ضرورية لحماية الصحة العامة والحد من مخاطر انتقال الأمراض أثناء السفر الدولي.

فرصة

التطورات في تكنولوجيا اللقاحات

وتوفر منصات اللقاحات الناشئة، مثل لقاحات mRNA ولقاحات النواقل الفيروسية، فرصًا جديدة لتطوير لقاحات السفر. وتسمح هذه المنصات المبتكرة بتصميم وإنتاج لقاحات سريعة ضد مجموعة واسعة من مسببات الأمراض، بما في ذلك تلك المسؤولة عن الأمراض المرتبطة بالسفر. ومن خلال الاستفادة من منصات اللقاحات الجديدة، يمكن للباحثين تسريع تطوير لقاحات السفر من الجيل التالي ذات الفعالية المحسنة والتغطية الأوسع ضد أمراض متعددة.

إن التقدم في تكنولوجيا اللقاحات يتيح تصميم لقاحات ذات مناعة معززة، مما يؤدي إلى استجابات مناعية أقوى وأطول أمدًا. تعمل المواد المساعدة الجديدة وأنظمة التوصيل واستراتيجيات تصميم المستضدات على تعزيز فعالية اللقاح من خلال تحفيز الاستجابات المناعية القوية وتحفيز المناعة الوقائية ضد مسببات الأمراض المستهدفة. ومن خلال تحسين فعالية اللقاح، تعمل التطورات التكنولوجية على زيادة فعالية لقاحات السفر في الوقاية من الأمراض والحد من خطر الإصابة بين المسافرين.

القيود / التحديات

متطلبات سلسلة التبريد للتخزين

إن البنية الأساسية لسلسلة التبريد، بما في ذلك معدات التبريد وأجهزة مراقبة درجة الحرارة ومرافق التخزين، ضرورية للحفاظ على فعالية اللقاح أثناء التخزين والنقل. ومع ذلك، تفتقر العديد من المناطق، وخاصة في البلدان المنخفضة والمتوسطة الدخل والمناطق النائية، إلى البنية الأساسية الكافية لسلسلة التبريد. إن غياب الكهرباء الموثوقة ومرافق التبريد وشبكات النقل يعقد إدارة سلسلة التبريد ويعرض ظروف تخزين اللقاح للخطر. ونتيجة لذلك، قد يكون توزيع اللقاح والوصول إليه محدودًا في المناطق التي تعاني من نقص البنية الأساسية لسلسلة التبريد، مما يعيق نمو سوق لقاحات السفر.

يجب تخزين اللقاحات ونقلها ضمن نطاق درجة حرارة محدد لمنع التعرض للحرارة أو البرودة التي قد تؤثر على فعاليتها. ومع ذلك، فإن التقلبات في درجات الحرارة أثناء النقل، مثل التعرض للحرارة الشديدة أو درجات الحرارة المتجمدة، يمكن أن تلحق الضرر باللقاحات وتجعلها غير فعالة. قد يكون ضمان استقرار درجة الحرارة ومراقبتها أثناء النقل أمرًا صعبًا، خاصة في المناطق ذات الظروف البيئية القاسية أو أنظمة النقل غير الموثوقة. تواجه اللقاحات الحساسة للحرارة، مثل تلك التي تتطلب تخزينًا في درجات حرارة منخفضة للغاية، تحديات إضافية في الحفاظ على الاستقرار أثناء النقل، مما يزيد من تعقيد إدارة سلسلة التبريد ويحد من إمكانية الوصول إلى اللقاح.

ارتفاع تكلفة لقاحات السفر

بالنسبة للعديد من الأفراد، وخاصة أولئك الذين يسافرون بميزانية محدودة أو إلى بلدان منخفضة الدخل، قد تكون تكلفة لقاحات السفر باهظة الثمن. وقد يضطر المسافرون إلى دفع ثمن اللقاحات من جيوبهم الخاصة، حيث لا تغطيها خطط التأمين الصحي دائمًا. وقد تتراكم التكلفة التراكمية للقاحات المتعددة الموصى بها للسفر إلى مناطق معينة بسرعة، مما يدفع بعض المسافرين إلى التخلي عن التطعيم تمامًا أو إعطاء الأولوية لنفقات السفر الأخرى على التطعيم. ونتيجة لذلك، قد تردع التكلفة المرتفعة للقاحات السفر بعض الأفراد عن طلب خدمات التطعيم، وبالتالي الحد من نمو سوق لقاحات السفر.

إن ارتفاع تكلفة لقاحات السفر يؤدي إلى تفاقم الفجوات القائمة في الوصول إلى خدمات الرعاية الصحية. فالأفراد من المجتمعات المهمشة أو المحرومة، الذين قد يواجهون بالفعل قيودًا مالية في الوصول إلى الرعاية الصحية، يتأثرون بشكل غير متناسب بالتكلفة المرتفعة للقاحات السفر. ويمكن أن يساهم هذا الوصول غير المتكافئ إلى خدمات التطعيم في فجوات في تغطية التطعيم بين المسافرين، وخاصة بين أولئك من خلفيات منخفضة الدخل. ونتيجة لذلك، قد يعوق نمو سوق لقاحات السفر الحواجز التي تحول دون الوصول والتي تفرضها التكلفة المرتفعة للقاحات.

التطورات الأخيرة

في مارس 2024، أعلنت شركة فايزر أن المفوضية الأوروبية منحت موافقة تسويق لقاح الشركة المكون من 20 لقاحًا ضد المكورات الرئوية، والذي يتم تسويقه في الاتحاد الأوروبي تحت الاسم التجاري PREVENAR 20، للتحصين النشط للوقاية من الأمراض الغازية والالتهاب الرئوي والتهاب الأذن الوسطى الحاد الناجم عن العقدية الرئوية عند الرضع والأطفال والمراهقين من سن 6 أسابيع إلى أقل من 18 عامًا.
في أكتوبر 2023، أعلنت شركة GSK plc. أنها توصلت إلى اتفاق حصري مع شركة Chongqing Zhifei Biological Products, Ltd. (Zhifei) للترويج للقاح Zhifei من GSK في الصين خلال السنوات الثلاث الأولى. يمكن استمرار التعاون بموافقة جميع الأطراف. استحوذت Zhifei، أكبر شركة لقاحات في الصين، على لقاحات مبتكرة من الصين. من خلال الجمع بين حجم وخبرة الشركتين، ستعمل الشراكة الاستراتيجية على توسيع نطاق توفر Shingrix بشكل كبير، ودعم التوسع السريع للقاح للمرضى والمؤشرات المحتملة في المستقبل.
في أكتوبر 2022، أعلنت شركة ميرك آند كو، المعروفة باسم إم إس دي خارج الولايات المتحدة وكندا، اليوم أن المفوضية الأوروبية وافقت على مؤشر موسع للقاح فاكسنيوفانس (لقاح المكورات الرئوية المقترن ذو الـ 15 تكافؤًا)، والذي يتضمن التحصين النشط للوقاية. لعلاج الأمراض الغازية والالتهاب الرئوي والتهاب الأذن الوسطى الحاد المتأثر بالمكورات الرئوية (S. pneumoniae) عند الرضع والأطفال والمراهقين من سن 6 أسابيع إلى أقل من 18 عامًا. تسهل الموافقة توفر لقاح فاكسنيوفانس لهذه الفئة من السكان في جميع الدول الأعضاء السبع والعشرين في الاتحاد الأوروبي، وكذلك في أيسلندا والنرويج وليختنشتاين
في سبتمبر 2022، أعلنت شركة أسترازينيكا أن جرعات FLUMIST QUADRIVALENT (لقاح الإنفلونزا الحي، عن طريق الأنف) متاحة الآن في الولايات المتحدة لموسم الإنفلونزا 2022-2023. FLUMIST QUADRIVALENT، لقاح الإنفلونزا الوحيد المعتمد من إدارة الغذاء والدواء (FDA)، مخصص للأعمار من 2 إلى 49.1 عامًا. وفقًا لتوصيات لجنة استشارية لممارسات التحصين (ACIP) من مراكز السيطرة على الأمراض والوقاية منها (CDC) للفترة 2022-2023. والأكاديمية الأمريكية لطب الأطفال (AAP)، يظل FLUMIST QUADRIVALENT بديلاً عن لقاح الإنفلونزا في الولايات المتحدة هذا الموسم. تؤكد مراكز السيطرة على الأمراض والوقاية منها أن الحماية الأكثر فعالية ضد الإنفلونزا الموسمية هي لقاح الإنفلونزا السنوي. ستساعد هذه الموافقة الشركة على توسيع أعمالها
في فبراير 2021، أعلنت شركة Johnson & Johnson Services Inc. أن إدارة الغذاء والدواء الأمريكية (FDA) قد منحت ترخيص الاستخدام الطارئ (EUA) للقاح COVID-19 أحادي الجرعة، الذي أنشأته شركات Janssen Pharmacetical Companies التابعة لشركة Johnson & Johnson، لمنع COVID-19 لدى الأفراد الذين تبلغ أعمارهم 18 عامًا أو أكثر. وقد ساعد هذا الشركة على تعزيز مجموعة منتجاتها

نطاق سوق لقاحات السفر العالمية

ينقسم سوق لقاحات السفر العالمية إلى تسعة قطاعات بارزة تعتمد على التركيب والنوع والفئة والمرض وطريقة الإدارة والجنس ونوع المريض والفئة العمرية وقناة التوزيع. يساعدك النمو بين القطاعات على تحليل جيوب النمو والاستراتيجيات المتخصصة للتعامل مع السوق وتحديد مجالات التطبيق الأساسية والاختلافات في أسواقك المستهدفة.

تعبير

اللقاحات المركبة
لقاحات أحادية

على أساس التركيب، يتم تقسيم السوق إلى لقاحات مركبة ولقاحات أحادية.

يكتب

اللقاحات المعطلة
اللقاحات الفرعية، واللقاحات المعاد تركيبها، واللقاحات متعددة السكاريد، واللقاحات المقترنة
اللقاحات الحية المضعفة
لقاحات التوكسويد
لقاحات الحمض النووي
لقاحات النواقل الفيروسية

على أساس النوع، يتم تقسيم السوق إلى لقاحات غير نشطة، ولقاحات فرعية، ولقاحات معاد تركيبها، ولقاحات متعددة السكاريد ومقترنة، ولقاحات حية مضعفة، ولقاحات توكسيد، ولقاحات الحمض النووي، ولقاحات ناقلات فيروسية.

فئة

اللقاح الموصى به
اللقاح الروتيني
اللقاح المطلوب

على أساس الفئة، يتم تقسيم السوق إلى لقاح موصى به، ولقاح روتيني، ولقاح مطلوب.

مرض

التيفوئيد
التهاب الكبد
كوليرا
جدري الماء
الانفلونزا
التهاب الدماغ الياباني
التهاب السحايا بالمكورات السحائية
حمى صفراء
داء الكلب
العلاج الطبيعي
الحصبة والنكاف
التهاب الدماغ المنقول بالقراد
ملاريا
كوفيد-19
شلل الأطفال
آحرون

على أساس المرض، يتم تقسيم السوق إلى التيفوئيد والتهاب الكبد والكوليرا وجدري الماء والإنفلونزا والتهاب الدماغ الياباني والتهاب السحايا والمكورات السحائية والحمى الصفراء وداء الكلب واللقاح الثلاثي والحصبة والنكاف والتهاب الدماغ المنقول بالقراد والملاريا وكوفيد-19 وشلل الأطفال وغيرها.

طريق الإدارة

قابلة للحقن
شفوي

على أساس طريق الإدارة، يتم تقسيم السوق إلى حقن وفموي.

جنس

ذكر
أنثى

على أساس الجنس، يتم تقسيم السوق إلى الذكور والإناث.

نوع المريض

بالغ
طب الأطفال
كبار السن

على أساس نوع المريض، يتم تقسيم السوق إلى البالغين والأطفال وكبار السن.

الفئة العمرية

20-50 سنة
أقل من 20 سنة
فوق 50 سنة

على أساس الفئة العمرية، يتم تقسيم السوق إلى 20-50 عامًا، وأقل من 20 عامًا، وفوق 50 عامًا.

قناة التوزيع

ب2ب
ب2م

على أساس قناة التوزيع، يتم تقسيم السوق إلى B2B و B2C.

تحليل/رؤى إقليمية لسوق لقاحات السفر العالمية

يتم تقسيم سوق لقاحات السفر العالمية إلى تسعة قطاعات بارزة تعتمد على التركيب والنوع والفئة والمرض وطريقة الإدارة والجنس ونوع المريض والفئة العمرية وقناة التوزيع.

الدول المشمولة في تقرير السوق هذا هي الولايات المتحدة وكندا والمكسيك وألمانيا والمملكة المتحدة وفرنسا وإيطاليا وهولندا وإسبانيا وروسيا وسويسرا وبولندا والنرويج والمجر والنمسا وأيرلندا وليتوانيا وبقية أوروبا والصين واليابان والهند وكوريا الجنوبية وأستراليا وسنغافورة وتايلاند وإندونيسيا وماليزيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ والبرازيل والأرجنتين وبيرو وبقية دول أمريكا الجنوبية والمملكة العربية السعودية والإمارات العربية المتحدة وإسرائيل وجنوب إفريقيا ومصر والكويت وبقية دول الشرق الأوسط وأفريقيا.

من المتوقع أن تهيمن أمريكا الشمالية على سوق لقاحات السفر العالمية بفضل سياسات السداد المواتية لعلاج غسيل الكلى. ومن المتوقع أن تهيمن الولايات المتحدة على منطقة أمريكا الشمالية بسبب وجود لاعبين رئيسيين في السوق وتحسين التطوير والبحث في قطاع الرعاية الصحية. ومن المتوقع أن تهيمن الهند على منطقة آسيا والمحيط الهادئ بسبب مساحتها الشاسعة ومجموعة كبيرة من المرضى المسنين. ومن المتوقع أن تهيمن ألمانيا على منطقة أوروبا بسبب تبنيها للتكنولوجيا المتقدمة والبنية التحتية القوية للرعاية الصحية والسوق الناضجة.

كما يوفر قسم الدولة في التقرير عوامل فردية مؤثرة على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود العلامات التجارية العالمية وتوافرها والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.

تحليل المشهد التنافسي وحصة سوق لقاحات السفر العالمية

يوفر المشهد التنافسي لسوق لقاحات السفر العالمية تفاصيل عن المنافسين. تتضمن التفاصيل نظرة عامة على الشركة، والمالية، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وموافقات المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق، ومنحنى شريان الحياة لنوع المنتج. تتعلق نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة على سوق لقاحات السفر العالمية.

بعض اللاعبين الرئيسيين في السوق العاملة في سوق لقاحات السفر العالمية هم GSK plc. و Bavarian Nordic و Pfizer Inc. و Abbott و CSL و AstraZeneca و Sanofi و Merck & Co.، Inc. و Valneva SE و Johnson & Johnson Services Inc. و Dynavax Technologies، من بين آخرين.

SKU-52745

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

انقر على الصورة للتكبير

لوحة معلومات تحليل البيانات التفاعلية
لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
تحليل المنافسين باستخدام لوحة معلومات تفاعلية
آخر الأخبار والتحديثات وتحليل الاتجاهات
استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل

طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL TRAVEL VACCINES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 PIPELINE ANALYSIS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES

5.1.2 INCREASING TRAVEL AND TOURISM

5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION

5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS

5.2 RESTRAINTS

5.2.1 HIGH COST OF TRAVEL VACCINES

5.2.2 REGULATORY HURDLES FOR APPROVAL

5.3 OPPORTUNITIES

5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY

5.3.2 GROWING AWARENESS REGARDING VACCINES

5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS

5.4 CHALLENGES

5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE

5.4.2 VACCINE HESITANCY AND MISINFORMATION

6 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION

6.1 OVERVIEW

6.2 COMBINATION VACCINES

6.3 MONO VACCINES

7 GLOBAL TRAVEL VACCINE MARKET, BY TYPE

7.1 OVERVIEW

7.2 INACTIVATED VACCINES

7.2.1 HEPATITIS A

7.2.2 INFLUENZA

7.2.3 RABIES

7.2.4 TICK-BORNE ENCEPHALITIS

7.2.5 JAPANESE ENCEPHALITIS

7.2.6 POLIO

7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES

7.3.1 HEPATITIS B

7.3.2 MENINGOCOCCAL

7.3.3 MALARIA

7.3.4 COVID-19

7.4 LIVE-ATTENUATED VACCINES

7.4.1 TYPHOID

7.4.2 CHOLERA

7.4.3 YELLOW FEVER

7.4.4 MEASLES

7.4.5 MUMPS

7.4.6 RUBELLA

7.4.7 VARICELLA

7.4.8 OTHERS

7.5 TOXOID VACCINES

7.5.1 DIPHTHERIA

7.5.2 TETANUS

7.6 DNA VACCINES

7.7 VIRAL VECTOR VACCINES

8 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY

8.1 OVERVIEW

8.2 RECOMMENDED VACCINE

8.2.1 TYPHOID FEVER VACCINES

8.2.2 HEPATITIS A

8.2.3 CHOLERA

8.2.4 RABIES

8.2.5 TICK-BORNE ENCEPHALITIS

8.2.6 JAPANESE ENCEPHALITIS

8.2.7 MALARIA

8.2.8 OTHERS

8.3 ROUTINE VACCINE

8.3.1 HEPATITIS B

8.3.2 INFLUENZA VACCINES

8.3.3 PNEUMOCOCCAL

8.3.4 DIPHTHERIA

8.3.5 TETANUS

8.3.6 MEASLES

8.3.7 MUMPS

8.3.8 RUBELLA

8.3.9 PERTUSSIS

8.3.10 OTHERS

8.4 REQUIRED VACCINE

8.4.1 YELLOW FEVER

8.4.2 MENINGOCOCCAL

8.4.3 POLIO VACCINES

9 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE

9.1 OVERVIEW

9.2 TYPHOID

9.3 HEPATITIS

9.3.1 HEPATITIS A

9.3.2 HEPATITIS B

9.4 CHOLERA

9.5 VARICELLA

9.6 INFLUENZA

9.7 JAPANESE ENCEPHALITIS

9.8 MENINGOCOCCAL MENINGITIS

9.9 YELLOW FEVER

9.1 RABIES

9.11 DPT

9.12 MEASLES AND MUMPS

9.13 TICK-BORNE ENCEPHALITIS

9.14 MALARIA

9.15 COVID-19

9.16 POLIO

9.17 OTHERS

10 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 INJECTABLE

10.2.1 INTRAMUSCULAR

10.2.2 SUBCUTANEOUS

10.2.3 OTHERS

10.3 ORAL

11 GLOBAL TRAVEL VACCINE MARKET, BY GENDER

11.1 OVERVIEW

11.2 MALE

11.3 FEMALE

12 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.3 PEDIATRIC

12.4 GERIATRIC

13 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP

13.1 OVERVIEW

13.2 20-50 YEARS

13.3 LESS THAN 20 YEARS

13.4 ABOVE 50 YEARS

14 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 B2B

14.3 B2C

15 GLOBAL TRAVEL VACCINE MARKET, BY REGION

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 ASIA-PACIFIC

15.3.1 INDIA

15.3.2 CHINA

15.3.3 MALAYSIA

15.3.4 SOUTH KOREA

15.3.5 JAPAN

15.3.6 AUSTRALIA

15.3.7 THAILAND

15.3.8 VIETNAM

15.3.9 SINGAPORE

15.3.10 INDONESIA

15.3.11 PHILIPPINES

15.3.12 REST OF ASIA-PACIFIC

15.4 EUROPE

15.4.1 GERMANY

15.4.2 U.K.

15.4.3 FRANCE

15.4.4 RUSSIA

15.4.5 ITALY

15.4.6 SPAIN

15.4.7 POLAND

15.4.8 NETHERLANDS

15.4.9 SWITZERLAND

15.4.10 HUNGARY

15.4.11 AUSTRIA

15.4.12 IRELAND

15.4.13 NORWAY

15.4.14 LITHUANIA

15.4.15 REST OF EUROPE

15.5 MIDDLE EAST AND AFRICA

15.5.1 SAUDI ARABIA

15.5.2 EGYPT

15.5.3 SOUTH AFRICA

15.5.4 KUWAIT

15.5.5 U.A.E.

15.5.6 ISRAEL

15.5.7 REST OF MIDDLE EAST AND AFRICA

15.6 SOUTH AMERICA

15.6.1 ARGENTINA

15.6.2 BRAZIL

15.6.3 PERU

15.6.4 REST OF SOUTH AMERICA

16 GLOBAL TRAVEL VACCINE MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PFIZER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 SANOFI

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 JOHNSON & JOHNSON SERVICES INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 GSK PLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 MERCK & CO., INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ASTRAZENECA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 BAVARIAN NORDIC

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 CSL

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 DYNAVAX TECHNOLOGIES.

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENTS

18.11 VALNEVA SE

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 PIPELINE ANALYSIS OF TRAVEL VACCINES MARKET

TABLE 2 VACCINES RECOMMENDATION FOR INTERNATIONAL TRAVELERS

TABLE 3 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 4 GLOBAL COMBINATION VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 5 GLOBAL MONO VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 6 GLOBAL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 7 GLOBAL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 8 GLOBAL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 9 GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 10 GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 11 GLOBAL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 12 GLOBAL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 13 GLOBAL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 14 GLOBAL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 15 GLOBAL DNA VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 16 GLOBAL VIRAL VECTOR VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 17 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 18 GLOBAL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 19 GLOBAL RECOMMENDED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 20 GLOBAL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 21 GLOBAL ROUTINE VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 22 GLOBAL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 23 GLOBAL REQUIRED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 24 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 25 GLOBAL TYPHOID IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 26 GLOBAL HEPATITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 27 GLOBAL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 28 GLOBAL CHOLERA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 29 GLOBAL VARICELLA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 30 GLOBAL INFLUENZA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 31 GLOBAL JAPANESE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 32 GLOBAL MENINGOCOCCAL MENINGITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 33 GLOBAL YELLOW FEVER IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 34 GLOBAL RABIES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 35 GLOBAL DPT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 36 GLOBAL MEASLES AND MUMPS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 37 GLOBAL TICK-BORNE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 38 GLOBAL MALARIA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 39 GLOBAL COVID-19 IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 40 GLOBAL POLIO IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 41 GLOBAL OTHERS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 42 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 43 GLOBAL INJECTABLE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 44 GLOBAL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 45 GLOBAL ORAL IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 46 GLOBAL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 47 GLOBAL MALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 48 GLOBAL FEMALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 49 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 50 GLOBAL ADULT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 51 GLOBAL PEDIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 52 GLOBAL GERIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 53 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 54 GLOBAL 20-50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 55 GLOBAL LESS THAN 20 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 56 GLOBAL ABOVE 50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 57 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 58 GLOBAL B2B IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 59 GLOBAL B2C IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 60 GLOBAL TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 61 NORTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 62 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 63 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 64 NORTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 65 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 66 NORTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 67 NORTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 68 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 69 NORTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 70 NORTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 71 NORTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 72 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 73 NORTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 74 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 75 NORTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 76 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 77 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 78 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 79 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 80 U.S. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 81 U.S. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 82 U.S. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 83 U.S. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 84 U.S. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 85 U.S. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 86 U.S. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 87 U.S. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 88 U.S. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 89 U.S. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 90 U.S. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 91 U.S. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 92 U.S. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 93 U.S. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 94 U.S. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 95 U.S. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 96 U.S. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 97 U.S. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 98 CANADA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 99 CANADA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 100 CANADA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 101 CANADA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 102 CANADA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 103 CANADA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 104 CANADA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 105 CANADA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 106 CANADA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 107 CANADA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 108 CANADA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 109 CANADA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 110 CANADA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 111 CANADA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 112 CANADA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 113 CANADA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 114 CANADA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 115 CANADA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 116 MEXICO TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 117 MEXICO TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 118 MEXICO INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 119 MEXICO SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 120 MEXICO LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 121 MEXICO TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 122 MEXICO TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 123 MEXICO RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 124 MEXICO ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 125 MEXICO REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 126 MEXICO TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 127 MEXICO HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 128 MEXICO TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 129 MEXICO INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 130 MEXICO TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 131 MEXICO TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 132 MEXICO TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 133 MEXICO TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 134 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 135 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 136 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 137 ASIA-PACIFIC INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 138 ASIA-PACIFIC SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 139 ASIA-PACIFIC LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 140 ASIA-PACIFIC TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 141 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 142 ASIA-PACIFIC RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 143 ASIA-PACIFIC ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 144 ASIA-PACIFIC REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 145 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 146 ASIA-PACIFIC HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 147 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 148 ASIA-PACIFIC INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 149 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 150 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 151 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 152 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 153 INDIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 154 INDIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 155 INDIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 156 INDIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 157 INDIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 158 INDIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 159 INDIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 160 INDIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 161 INDIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 162 INDIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 163 INDIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 164 INDIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 165 INDIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 166 INDIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 167 INDIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 168 INDIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 169 INDIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 170 INDIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 171 CHINA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 172 CHINA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 173 CHINA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 174 CHINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 175 CHINA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 176 CHINA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 177 CHINA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 178 CHINA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 179 CHINA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 180 CHINA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 181 CHINA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 182 CHINA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 183 CHINA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 184 CHINA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 185 CHINA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 186 CHINA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 187 CHINA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 188 CHINA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 189 MALAYSIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 190 MALAYSIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 191 MALAYSIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 192 MALAYSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 193 MALAYSIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 194 MALAYSIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 195 MALAYSIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 196 MALAYSIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 197 MALAYSIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 198 MALAYSIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 199 MALAYSIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 200 MALAYSIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 201 MALAYSIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 202 MALAYSIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 203 MALAYSIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 204 MALAYSIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 205 MALAYSIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 206 MALAYSIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 207 SOUTH KOREA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 208 SOUTH KOREA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 209 SOUTH KOREA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 210 SOUTH KOREA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 211 SOUTH KOREA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 212 SOUTH KOREA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 213 SOUTH KOREA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 214 SOUTH KOREA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 215 SOUTH KOREA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 216 SOUTH KOREA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 217 SOUTH KOREA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 218 SOUTH KOREA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 219 SOUTH KOREA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 220 SOUTH KOREA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 221 SOUTH KOREA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 222 SOUTH KOREA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 223 SOUTH KOREA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 224 SOUTH KOREA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 225 JAPAN TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 226 JAPAN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 227 JAPAN INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 228 JAPAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 229 JAPAN LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 230 JAPAN TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 231 JAPAN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 232 JAPAN RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 233 JAPAN ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 234 JAPAN REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 235 JAPAN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 236 JAPAN HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 237 JAPAN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 238 JAPAN INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 239 JAPAN TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 240 JAPAN TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 241 JAPAN TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 242 JAPAN TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 243 AUSTRALIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 244 AUSTRALIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 245 AUSTRALIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 246 AUSTRALIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 247 AUSTRALIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 248 AUSTRALIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 249 AUSTRALIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 250 AUSTRALIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 251 AUSTRALIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 252 AUSTRALIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 253 AUSTRALIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 254 AUSTRALIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 255 AUSTRALIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 256 AUSTRALIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 257 AUSTRALIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 258 AUSTRALIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 259 AUSTRALIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 260 AUSTRALIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 261 THAILAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 262 THAILAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 263 THAILAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 264 THAILAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 265 THAILAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 266 THAILAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 267 THAILAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 268 THAILAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 269 THAILAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 270 THAILAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 271 THAILAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 272 THAILAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 273 THAILAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 274 THAILAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 275 THAILAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 276 THAILAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 277 THAILAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 278 THAILAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 279 VIETNAM TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 280 VIETNAM TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 281 VIETNAM INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 282 VIETNAM SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 283 VIETNAM LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 284 VIETNAM TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 285 VIETNAM TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 286 VIETNAM RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 287 VIETNAM ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 288 VIETNAM REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 289 VIETNAM TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 290 VIETNAM HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 291 VIETNAM TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 292 VIETNAM INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 293 VIETNAM TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 294 VIETNAM TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 295 VIETNAM TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 296 VIETNAM TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 297 SINGAPORE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 298 SINGAPORE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 299 SINGAPORE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 300 SINGAPORE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 301 SINGAPORE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 302 SINGAPORE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 303 SINGAPORE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 304 SINGAPORE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 305 SINGAPORE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 306 SINGAPORE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 307 SINGAPORE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 308 SINGAPORE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 309 SINGAPORE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 310 SINGAPORE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 311 SINGAPORE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 312 SINGAPORE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 313 SINGAPORE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 314 SINGAPORE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 315 INDONESIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 316 INDONESIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 317 INDONESIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 318 INDONESIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 319 INDONESIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 320 INDONESIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 321 INDONESIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 322 INDONESIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 323 INDONESIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 324 INDONESIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 325 INDONESIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 326 INDONESIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 327 INDONESIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 328 INDONESIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 329 INDONESIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 330 INDONESIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 331 INDONESIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 332 INDONESIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 333 PHILIPPINES TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 334 PHILIPPINES TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 335 PHILIPPINES INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 336 PHILIPPINES SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 337 PHILIPPINES LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 338 PHILIPPINES TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 339 PHILIPPINES TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 340 PHILIPPINES RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 341 PHILIPPINES ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 342 PHILIPPINES REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 343 PHILIPPINES TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 344 PHILIPPINES HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 345 PHILIPPINES TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 346 PHILIPPINES INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 347 PHILIPPINES TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 348 PHILIPPINES TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 349 PHILIPPINES TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 350 PHILIPPINES TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 351 REST OF ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 352 EUROPE TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 353 EUROPE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 354 EUROPE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 355 EUROPE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 356 EUROPE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 357 EUROPE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 358 EUROPE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 359 EUROPE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 360 EUROPE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 361 EUROPE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 362 EUROPE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 363 EUROPE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 364 EUROPE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 365 EUROPE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 366 EUROPE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 367 EUROPE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 368 EUROPE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 369 EUROPE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 370 EUROPE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 371 GERMANY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 372 GERMANY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 373 GERMANY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 374 GERMANY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 375 GERMANY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 376 GERMANY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 377 GERMANY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 378 GERMANY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 379 GERMANY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 380 GERMANY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 381 GERMANY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 382 GERMANY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 383 GERMANY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 384 GERMANY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 385 GERMANY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 386 GERMANY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 387 GERMANY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 388 GERMANY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 389 U.K. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 390 U.K. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 391 U.K. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 392 U.K. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 393 U.K. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 394 U.K. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 395 U.K. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 396 U.K. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 397 U.K. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 398 U.K. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 399 U.K. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 400 U.K. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 401 U.K. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 402 U.K. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 403 U.K. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 404 U.K. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 405 U.K. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 406 U.K. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 407 FRANCE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 408 FRANCE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 409 FRANCE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 410 FRANCE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 411 FRANCE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 412 FRANCE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 413 FRANCE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 414 FRANCE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 415 FRANCE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 416 FRANCE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 417 FRANCE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 418 FRANCE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 419 FRANCE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 420 FRANCE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 421 FRANCE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 422 FRANCE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 423 FRANCE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 424 FRANCE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 425 RUSSIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 426 RUSSIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 427 RUSSIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 428 RUSSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 429 RUSSIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 430 RUSSIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 431 RUSSIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 432 RUSSIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 433 RUSSIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 434 RUSSIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 435 RUSSIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 436 RUSSIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 437 RUSSIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 438 RUSSIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 439 RUSSIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 440 RUSSIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 441 RUSSIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 442 RUSSIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 443 ITALY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 444 ITALY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 445 ITALY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 446 ITALY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 447 ITALY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 448 ITALY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 449 ITALY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 450 ITALY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 451 ITALY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 452 ITALY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 453 ITALY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 454 ITALY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 455 ITALY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 456 ITALY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 457 ITALY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 458 ITALY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 459 ITALY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 460 ITALY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 461 SPAIN TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 462 SPAIN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 463 SPAIN INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 464 SPAIN SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 465 SPAIN LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 466 SPAIN TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 467 SPAIN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 468 SPAIN RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 469 SPAIN ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 470 SPAIN REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 471 SPAIN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 472 SPAIN HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 473 SPAIN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 474 SPAIN INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 475 SPAIN TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 476 SPAIN TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 477 SPAIN TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 478 SPAIN TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 479 POLAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 480 POLAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 481 POLAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 482 POLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 483 POLAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 484 POLAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 485 POLAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 486 POLAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 487 POLAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 488 POLAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 489 POLAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 490 POLAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 491 POLAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 492 POLAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 493 POLAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 494 POLAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 495 POLAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 496 POLAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 497 NETHERLANDS TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 498 NETHERLANDS TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 499 NETHERLANDS INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 500 NETHERLANDS SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 501 NETHERLANDS LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 502 NETHERLANDS TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 503 NETHERLANDS TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 504 NETHERLANDS RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 505 NETHERLANDS ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 506 NETHERLANDS REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 507 NETHERLANDS TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 508 NETHERLANDS HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 509 NETHERLANDS TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 510 NETHERLANDS INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 511 NETHERLANDS TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 512 NETHERLANDS TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 513 NETHERLANDS TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 514 NETHERLANDS TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 515 SWITZERLAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 516 SWITZERLAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 517 SWITZERLAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 518 SWITZERLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 519 SWITZERLAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 520 SWITZERLAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 521 SWITZERLAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 522 SWITZERLAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 523 SWITZERLAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 524 SWITZERLAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 525 SWITZERLAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 526 SWITZERLAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 527 SWITZERLAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 528 SWITZERLAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 529 SWITZERLAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 530 SWITZERLAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 531 SWITZERLAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 532 SWITZERLAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 533 HUNGARY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 534 HUNGARY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 535 HUNGARY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 536 HUNGARY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 537 HUNGARY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 538 HUNGARY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 539 HUNGARY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 540 HUNGARY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 541 HUNGARY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 542 HUNGARY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 543 HUNGARY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 544 HUNGARY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 545 HUNGARY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 546 HUNGARY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 547 HUNGARY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 548 HUNGARY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 549 HUNGARY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 550 HUNGARY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 551 AUSTRIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 552 AUSTRIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 553 AUSTRIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 554 AUSTRIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 555 AUSTRIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 556 AUSTRIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 557 AUSTRIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 558 AUSTRIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 559 AUSTRIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 560 AUSTRIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 561 AUSTRIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 562 AUSTRIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 563 AUSTRIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 564 AUSTRIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 565 AUSTRIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 566 AUSTRIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 567 AUSTRIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 568 AUSTRIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 569 IRELAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 570 IRELAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 571 IRELAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 572 IRELAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 573 IRELAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 574 IRELAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 575 IRELAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 576 IRELAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 577 IRELAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 578 IRELAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 579 IRELAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 580 IRELAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 581 IRELAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 582 IRELAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 583 IRELAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 584 IRELAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 585 IRELAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 586 IRELAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 587 NORWAY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 588 NORWAY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 589 NORWAY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 590 NORWAY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 591 NORWAY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 592 NORWAY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 593 NORWAY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 594 NORWAY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 595 NORWAY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 596 NORWAY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 597 NORWAY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 598 NORWAY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 599 NORWAY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 600 NORWAY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 601 NORWAY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 602 NORWAY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 603 NORWAY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 604 NORWAY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 605 LITHUANIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 606 LITHUANIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 607 LITHUANIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 608 LITHUANIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 609 LITHUANIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 610 LITHUANIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 611 LITHUANIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 612 LITHUANIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 613 LITHUANIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 614 LITHUANIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 615 LITHUANIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 616 LITHUANIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 617 LITHUANIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 618 LITHUANIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 619 LITHUANIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 620 LITHUANIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 621 LITHUANIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 622 LITHUANIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 623 REST OF EUROPE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 624 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 625 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 626 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 627 MIDDLE EAST AND AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 628 MIDDLE EAST AND AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 629 MIDDLE EAST AND AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 630 MIDDLE EAST AND AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 631 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 632 MIDDLE EAST AND AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 633 MIDDLE EAST AND AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 634 MIDDLE EAST AND AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 635 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 636 MIDDLE EAST AND AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 637 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 638 MIDDLE EAST AND AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 639 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 640 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 641 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 642 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 643 SAUDI ARABIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 644 SAUDI ARABIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 645 SAUDI ARABIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 646 SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 647 SAUDI ARABIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 648 SAUDI ARABIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 649 SAUDI ARABIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 650 SAUDI ARABIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 651 SAUDI ARABIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 652 SAUDI ARABIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 653 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 654 SAUDI ARABIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 655 SAUDI ARABIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 656 SAUDI ARABIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 657 SAUDI ARABIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 658 SAUDI ARABIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 659 SAUDI ARABIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 660 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 661 EGYPT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 662 EGYPT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 663 EGYPT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 664 EGYPT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 665 EGYPT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 666 EGYPT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 667 EGYPT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 668 EGYPT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 669 EGYPT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 670 EGYPT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 671 EGYPT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 672 EGYPT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 673 EGYPT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 674 EGYPT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 675 EGYPT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 676 EGYPT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 677 EGYPT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 678 EGYPT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 679 SOUTH AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 680 SOUTH AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 681 SOUTH AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 682 SOUTH AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 683 SOUTH AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 684 SOUTH AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 685 SOUTH AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 686 SOUTH AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 687 SOUTH AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 688 SOUTH AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 689 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 690 SOUTH AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 691 SOUTH AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 692 SOUTH AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 693 SOUTH AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 694 SOUTH AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 695 SOUTH AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 696 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 697 KUWAIT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 698 KUWAIT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 699 KUWAIT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 700 KUWAIT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 701 KUWAIT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 702 KUWAIT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 703 KUWAIT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 704 KUWAIT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 705 KUWAIT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 706 KUWAIT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 707 KUWAIT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 708 KUWAIT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 709 KUWAIT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 710 KUWAIT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 711 KUWAIT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 712 KUWAIT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 713 KUWAIT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 714 KUWAIT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 715 U.A.E. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 716 U.A.E. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 717 U.A.E. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 718 U.A.E. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 719 U.A.E. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 720 U.A.E. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 721 U.A.E. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 722 U.A.E. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 723 U.A.E. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 724 U.A.E. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 725 U.A.E. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 726 U.A.E. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 727 U.A.E. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 728 U.A.E. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 729 U.A.E. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 730 U.A.E. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 731 U.A.E. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 732 U.A.E. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 733 ISRAEL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 734 ISRAEL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 735 ISRAEL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 736 ISRAEL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 737 ISRAEL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 738 ISRAEL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 739 ISRAEL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 740 ISRAEL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 741 ISRAEL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 742 ISRAEL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 743 ISRAEL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 744 ISRAEL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 745 ISRAEL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 746 ISRAEL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 747 ISRAEL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 748 ISRAEL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 749 ISRAEL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 750 ISRAEL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 751 REST OF MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 752 SOUTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 753 SOUTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 754 SOUTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 755 SOUTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 756 SOUTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 757 SOUTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 758 SOUTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 759 SOUTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 760 SOUTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 761 SOUTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 762 SOUTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 763 SOUTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 764 SOUTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 765 SOUTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 766 SOUTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 767 SOUTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 768 SOUTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 769 SOUTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 770 SOUTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 771 ARGENTINA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 772 ARGENTINA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 773 ARGENTINA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 774 ARGENTINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 775 ARGENTINA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 776 ARGENTINA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 777 ARGENTINA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 778 ARGENTINA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 779 ARGENTINA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 780 ARGENTINA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 781 ARGENTINA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 782 ARGENTINA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 783 ARGENTINA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 784 ARGENTINA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 785 ARGENTINA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 786 ARGENTINA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 787 ARGENTINA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 788 ARGENTINA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 789 BRAZIL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 790 BRAZIL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 791 BRAZIL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 792 BRAZIL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 793 BRAZIL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 794 BRAZIL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 795 BRAZIL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 796 BRAZIL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 797 BRAZIL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 798 BRAZIL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 799 BRAZIL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 800 BRAZIL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 801 BRAZIL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 802 BRAZIL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 803 BRAZIL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 804 BRAZIL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 805 BRAZIL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 806 BRAZIL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 807 PERU TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 808 PERU TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 809 PERU INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 810 PERU SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 811 PERU LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 812 PERU TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 813 PERU TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 814 PERU RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 815 PERU ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 816 PERU REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 817 PERU TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 818 PERU HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 819 PERU TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 820 PERU INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 821 PERU TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 822 PERU TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 823 PERU TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 824 PERU TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 825 REST OF SOUTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

List of Figure

FIGURE 1 GLOBAL TRAVEL VACCINES MARKET: SEGMENTATION

FIGURE 2 GLOBAL TRAVEL VACCINES MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL TRAVEL VACCINES MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL TRAVEL VACCINES MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL TRAVEL VACCINES MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL TRAVEL VACCINES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL TRAVEL VACCINES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL TRAVEL VACCINES MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 GLOBAL TRAVEL VACCINES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL TRAVEL VACCINES MARKET: SEGMENTATION

FIGURE 11 RISING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION AMONG TRAVELERS ARE EXPECTED TO DRIVE THE GLOBAL TRAVEL VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2032

FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL TRAVEL VACCINES MARKET IN 2021 & 2032

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND THE GLOBAL TRAVEL VACCINES MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2032

FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR TRAVEL VACCINES MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2032

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL TRAVEL VACCINE MARKET

FIGURE 16 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, 2023

FIGURE 17 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, 2024-2032 (USD THOUSAND)

FIGURE 18 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION , CAGR (2024-2032)

FIGURE 19 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, LIFELINE CURVE

FIGURE 20 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, 2023

FIGURE 21 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, 2024-2032 (USD THOUSAND)

FIGURE 22 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, CAGR (2024-2032)

FIGURE 23 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, 2023

FIGURE 25 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, 2024-2032 (USD THOUSAND)

FIGURE 26 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, CAGR (2024-2032)

FIGURE 27 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, LIFELINE CURVE

FIGURE 28 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, 2023

FIGURE 29 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, 2024-2032 (USD THOUSAND)

FIGURE 30 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, CAGR (2024-2032)

FIGURE 31 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 32 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 33 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2032 (USD THOUSAND)

FIGURE 34 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2032)

FIGURE 35 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, 2023

FIGURE 37 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, 2024-2032 (USD THOUSAND)

FIGURE 38 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, CAGR (2024-2032)

FIGURE 39 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, LIFELINE CURVE

FIGURE 40 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2023

FIGURE 41 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2024-2032 (USD THOUSAND)

FIGURE 42 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, CAGR (2024-2032)

FIGURE 43 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 44 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, 2023

FIGURE 45 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, 2024-2032 (USD THOUSAND)

FIGURE 46 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, CAGR (2024-2032)

FIGURE 47 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 48 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 49 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2024-2032 (USD THOUSAND)

FIGURE 50 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2032)

FIGURE 51 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 GLOBAL TRAVEL VACCINE MARKET: SNAPSHOT (2023)

FIGURE 53 GLOBAL TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

FIGURE 54 NORTH AMERICA TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

FIGURE 55 EUROPE TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

FIGURE 56 AISA-PACIFIC TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

View Detailed Information

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

How big is the Travel Vaccine Market?

The Travel Vaccine Market size will be worth USD 13.09 billion by 2032.

What is the growth rate of the Travel Vaccine Market?

The Travel Vaccine Market growth rate is 8.9% by 2032.

What are the growth drivers of the Travel Vaccine Market?

Rising Incidence of Infectious Diseases, Government Regulations and Recommendations Regarding Vaccination are the growth drivers of the Travel Vaccine Market.

What are the factors on which the Travel Vaccine Market research is based on?

The composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel are the factors on which the Travel Vaccine Market research is based.

Which are the major companies in the Travel Vaccine Market?

The major companies in the Travel Vaccine Market are GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc., and Dynavax Technologies.

سوق لقاحات السفر العالمية – اتجاهات الصناعة والتوقعات حتى عام 2032

سوق لقاحات السفر العالمية – اتجاهات الصناعة والتوقعات حتى عام 2032

تحليل ورؤى حول سوق لقاحات السفر

ديناميكيات سوق لقاحات السفر العالمية

نطاق سوق لقاحات السفر العالمية

تحليل/رؤى إقليمية لسوق لقاحات السفر العالمية

تحليل المشهد التنافسي وحصة سوق لقاحات السفر العالمية

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Table of Content

List of Table

List of Figure

منهجية البحث

التخصيص متاح

Frequently Asked Questions

التقارير

رؤى السوق

يدعم

حلول

سوق لقاحات السفر العالمية – اتجاهات الصناعة والتوقعات حتى عام 2032

سوق لقاحات السفر العالمية – اتجاهات الصناعة والتوقعات حتى عام 2032

تحليل ورؤى حول سوق لقاحات السفر

ديناميكيات سوق لقاحات السفر العالمية

نطاق سوق لقاحات السفر العالمية

تحليل/رؤى إقليمية لسوق لقاحات السفر العالمية

تحليل المشهد التنافسي وحصة سوق لقاحات السفر العالمية

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Table of Content

List of Table

List of Figure

منهجية البحث

التخصيص متاح

Frequently Asked Questions

تصفح الصفحات ذات الصلة